Want to see IN:MEDICAMEQ full AI Analyst Report?

Medicamen Biotech Limited (MEDICAMEQ) Price & Analysis

0 Followers

MEDICAMEQ Stock Chart & Stats

₹366.90

-₹10.20(-1.97%)

At close: Jan 08 4:00 PM EST

₹366.90

-₹10.20(-1.97%)

Day’s Range― - ―

52-Week Range₹210.10 - ₹454.00

Previous CloseN/A

Volume10.37K

Average Volume (3M)4.34K

Market Cap

₹4.32B

Enterprise Value₹3.02K

Total Cash (Recent Filing)₹312.64M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)43.1

Beta1.21

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.29%

Share Statistics

EPS (TTM)8.01

Shares Outstanding13,562,815

10 Day Avg. Volume7,966

30 Day Avg. Volume4,337

Financial Highlights & Ratios

PEG Ratio1.06

Price to Book (P/B)1.08

Price to Sales (P/S)1.51

P/FCF Ratio-7.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Generic Formulation PlatformA finished-dosage portfolio spanning multiple therapeutic segments gives Medicamen Biotech several avenues for volume growth and customer coverage. Its combination of domestic distribution and exports broadens the commercial base, while generic medicines provide an established model for recurring demand.

Recent Revenue GrowthThe return to strong revenue growth in FY2026 indicates that the company retains the ability to expand its sales base despite prior volatility. If sustained, improved scale can support broader market reach and provide a foundation for rebuilding earnings through operating leverage.

Conservative Balance SheetModerate leverage and substantial equity growth provide financial resilience relative to a more heavily debt-funded structure. This balance-sheet position can preserve flexibility for working-capital needs, investment, and business continuity even while operating cash generation remains uneven.

Bears Say

Persistent Operating Cash OutflowsFour consecutive years of negative operating cash flow show that reported business activity is not converting reliably into cash. The large FY2026 outflow increases dependence on balance-sheet resources or external funding and can constrain the company’s ability to finance growth internally.

Recurring Negative Free Cash FlowSustained negative free cash flow reduces the cash available for reinvestment, debt service, or shareholder returns, even when the company reports accounting profits. The FY2026 deterioration suggests that cash needs may remain a durable constraint on capital allocation over coming quarters.

Weaker Profitability And ReturnsLower net income and declining returns on equity indicate that recent growth has not translated into proportionate profitability. Weaker earnings efficiency can limit internally generated capital and reduce the company’s ability to compound value from its expanding asset and equity base.

Medicamen Biotech Limited News

Medicamen Biotech Gets NSE Caution Over Compliance Observations

The latest announcement is out from Medicamen Biotech Limited ( ($IN:MEDICAMEQ) ). Medicamen Biotech Limited has disclosed that...

7M ago

MEDICAMEQ FAQ

What was Medicamen Biotech Limited’s price range in the past 12 months?

Medicamen Biotech Limited lowest stock price was ₹210.10 and its highest was ₹454.00 in the past 12 months.

What is Medicamen Biotech Limited’s market cap?

Medicamen Biotech Limited’s market cap is ₹4.32B.

When is Medicamen Biotech Limited’s upcoming earnings report date?

Medicamen Biotech Limited’s upcoming earnings report date is Nov 06, 2026 which is in 49 days.

How were Medicamen Biotech Limited’s earnings last quarter?

Medicamen Biotech Limited released its earnings results on Aug 14, 2026. The company reported ₹1.562 earnings per share for the quarter.

Is Medicamen Biotech Limited overvalued?

According to Wall Street analysts Medicamen Biotech Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medicamen Biotech Limited pay dividends?

Medicamen Biotech Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.29%. See more information on Medicamen Biotech Limited dividends here

What is Medicamen Biotech Limited’s EPS estimate?

Medicamen Biotech Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicamen Biotech Limited have?

Medicamen Biotech Limited has 13,562,815 shares outstanding.

What happened to Medicamen Biotech Limited’s price movement after its last earnings report?

Medicamen Biotech Limited reported an EPS of ₹1.562 in its last earnings report. Following the earnings report the stock price went down -0.824%.

Which hedge fund is a major shareholder of Medicamen Biotech Limited?

Currently, no hedge funds are holding shares in IN:MEDICAMEQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicamen Biotech Limited

Medicamen Biotech Limited, established in 1993 and headquartered in New Delhi, India, is an Indian pharmaceutical firm primarily engaged in the manufacturing and distribution of a diverse range of medicinal formulations. Its product line encompasses various dosage formats, including tablets, capsules, liquid and dry syrups, and topical ointments. The company further extends its portfolio to specialized items such as oral rehydration solutions, mouthwashes, and dental care products.